linjc16/ctgov huggingface dataset:
Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

Study Overview
=================
Brief Summary
-----------------
One hundred patients with moderate to severe asymptomatic aortic stenosis (AS) will be asked to exercise on a treadmill. NT-pro-BNP levels will be drawn before and after exercise. Changes in NT-pro-BNP levels will be correlated to outcomes at one year. In the pilot phase an additional 10 control subjects without AS will be enrolled to document the control response of NT-pro-BNP elevations with exercise.

Official Title
-----------------
Utility of Exercise-induced NT-pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

Conditions
-----------------
Aortic Stenosis

Intervention / Treatment
-----------------
* Other: NT-pro-BNP levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: valvular AS (Doppler velocity ≥ 3.0 m/s) no baseline symptoms referable to valvular heart disease able to perform ETT Exclusion Criteria: more than mild aortic regurgitation, mitral regurgitation/ stenosis, or tricuspid regurgitation/stenosis previous AVR known coronary artery disease creatinine clearance 50 mL/min LVEF < 50% planned valve surgery prior to enrollment significant pulmonary disease unable to give informed consent pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A<br>10 patients with no aortic stenosis | Other: NT-pro-BNP levels<br>* pre- and post-exercise NT-pro-BNP levels<br>|
| Other: B<br>100 patients with asymptomatic AS | Other: NT-pro-BNP levels<br>* pre- and post-exercise NT-pro-BNP levels<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of symptomatic aortic stenosis (new/progressive angina or dyspnea, pre-syncope/syncope, hospitalization for cardiac chest pain or heart failure, drop in LV ejection fraction, cardiovascular or sudden death, valve replacement surgery) |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aortic stenosis, prognosis, brain natriuretic peptide
Immediate Simultaneous Bilateral Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of treating visually significant bilateral cataract with the newer technique of Immediate Simultaneous Bilateral Cataract Surgery (ISBCS) versus the conventional technique of Delayed Sequential Bilateral Cataract Surgery (DSBCS) in a select patient population.

Official Title
-----------------
Immediate Simultaneous Bilateral Cataract Surgery: A Prospective, Case-controlled Clinical Trial in the United States

Conditions
-----------------
Bilateral Cataract

Intervention / Treatment
-----------------
* Procedure: ISBCS
* Procedure: DSBCS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 30-100 Candidate for topical anesthesia Signed the informed consents Exclusion Criteria: Allergies to medications used in study Cannot have topical anesthesia Unwilling to participate in research trial Have any other significant ocular comorbidities Have known systemic immuno-compromised state

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ISBCS<br>Immediate Simultaneous Bilateral Cataract Surgery | Procedure: ISBCS<br>* same-day cataract surgery<br>|
| Active Comparator: DSBCS<br>Delayed Sequential Bilateral Cataract Surgery | Procedure: DSBCS<br>* bilateral surgery delayed by 1-3 weeks amongst eyes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Best uncorrected and best spectacle corrected post-operative visual acuity | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recovery time and number of post-operative visits |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bilateral Cataract, Simultaneous Cataract Surgery, ISBCS
A Study of Tecogalan Sodium

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

Detailed Description
-----------------
Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.

Official Title
-----------------
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days

Conditions
-----------------
Sarcoma, Kaposi, HIV Infections

Intervention / Treatment
-----------------
* Drug: Tecogalan sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Kaposi's sarcoma plus HIV infection OR metastatic solid tumor. Life expectancy of at least 12 weeks. NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks. Recovered from toxicity of any prior anticancer therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Leukemia or lymphoma. Current gastrointestinal bleeding by stool guaiac. Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. Acute intercurrent infection other than genital herpes. Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. Concurrent Medication: Excluded: Other anticancer therapy. Other investigational agents. Patients with the following prior conditions are excluded: History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. History of myocardial infarction within past 6 months. Prior Medication: Excluded: Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C). Investigational agents within the past 4 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tecogalan sodium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neoplasms, Sarcoma, Kaposi, Acquired Immunodeficiency Syndrome, Antineoplastic Agents, tecogalan
NIV in Covid-19 Respiratory Failure

Study Overview
=================
Brief Summary
-----------------
A retrospective, single centre observational study to validate use of the HACOR score (Duan et al, 2017) in determining efficacy of non-invasive ventilation in Covid-19 respiratory failure.

Detailed Description
-----------------
The investigators will retrospectively analyse medical records of patients with confirmed Covid-19 respiratory failure who received continuous positive airway pressure (CPAP) via facemask, as per clinician decision, in the High Dependency Unit (HDU) or Intensive Care Unit (ICU) of University Hospital Crosshouse between 1st March 2020 and 30th April 2021. By collecting baseline demographics and physiological data (including APACHE II and clinical frailty score) and calculating the HACOR score at initiation of CPAP, then at 1hr, 6hrs, 12hrs, 24hrs and 48hrs after initiating CPAP the investigators aim to validate use of the HACOR score in determining efficacy of NIV in Covid-19 respiratory failure. The investigators will also collect other variables (CRP and lymphocytes, lactate, mean arterial pressure, temperature) to determine if these factors have utility in predicting efficacy of NIV in Covid-19 respiratory failure.

Official Title
-----------------
Non-invasive Ventilation in Covid-19 Respiratory Failure - Predicting Success: A Retrospective Observational Study to Determine Predictive Factors in the Success or Failure of Non-invasive Ventilation.

Conditions
-----------------
COVID-19 Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed Covid-19 respiratory failure NIV treatment instituted as per clinician decision Admitted to HDU or ICU between 1/3/20 and 30/4/21 Exclusion Criteria: Patients with immediate indication for invasive ventilation Patients whose primary diagnosis was not Covid-19 respiratory failure, but received NIV in that time period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Escalation to Invasive Ventilation | Number of patients who deteriorated after NIV commenced, requiring escalation to invasive ventilation | Up to 6 months | 
| Death Due to Respiratory Failure | Number of patients who deteriorated after NIV commenced, resulting in death due to respiratory failure | Up to 6 months | 
| Clinical Improvement | Number of patients who improved after NIV commenced, resulting in liberation from NIV (without requiring invasive ventilation) | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, HACOR, Non-Invasive Ventilation, CPAP
Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs

Study Overview
=================
Brief Summary
-----------------
Define the patients who lost HBsAg, studying the loss predictive factors and if there was suspension of treatment, study the evolution after that

Official Title
-----------------
Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs

Conditions
-----------------
Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old Chronic hepatitis B (HBeAg+ or HBeAg-) HBsAg loss Treated with nucleoside/nucleotide analogues With or without previous interferon (IFN/PEG-IFN) Patients with HBsAg loss after 2006 Immunocompetent patients Exclusion Criteria: Spontaneous HBsAg loss HBsAg loss while treatment in monotherapy or combinated with IFN or PEG-IFN. Patients with hepatitis delta virus (HDV) coinfection. Patients with hepatitis C virus (HCV) coinfection. Patients with HIV coinfection. Patients with liver transplant. Patients with reactivated hepatitis B virus (HBV) by immuno-suppressive treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with chronic hepatitis B treated with nRTI<br>Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiological characteristics from hepatitis B patients who lost HBsAg related to treatment with nucleoside/nucleotide analogues | Study the number of diferents virological, serological, clinical, histological, biochemical characteristics from hepatitis B patients who lost HBsAg related to treatment with nucleoside/nucleotide analogues. | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiological characteristics in case of suspension of treatment. | Count the diferents characteristics virological, histological, serological, and the clinical course of this patients whom must to be suspended the treatment | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nucleoside/nucleotide, HBsAg loss, Hepatitis B
Effect of Dairy Fat on Plasma Phytanic Acid in Human

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate if cow feeding regimes affects concentration of plasma phytanic acid and risk markers of the metabolic syndrome in human.

Official Title
-----------------
Effect of Dairy Fat on Plasma Phytanic Acid in Healthy Volunteers - A Randomized Controlled Study

Conditions
-----------------
Coronary Heart Disease

Intervention / Treatment
-----------------
* Dietary Supplement: milk fat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sign written consent Age: 20-42 BMI: 20-30 increased risk of developing MS refrain from dietary supplements and blood donations prior to, and during the study Exclusion Criteria: poor compliance if they suffering from any chronic or long lasting illness abuse of alcohol or medicine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: milk fat|45 g milk fat per day in 4 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma phytanic acid |  | before and after the intervention (4 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total cholesterol |  | before and after the intervention (4 weeks) | 
| LDL cholesterol |  | before and after the intervention (4 weeks) | 
| HDL cholesterol |  | before and after the intervention (4 weeks) | 
| triacylglycerol |  | before and after the intervention (4 weeks) | 
| C-reactive protein |  | before and after the intervention (4 weeks) | 
| insulin |  | before and after the intervention (4 weeks) | 
| glucose |  | before and after the intervention (4 weeks) | 
| fatty acid composition in plasma |  | before and after the intervention (4 weeks) |
Effect of Preoperative Anxiety on Postoperative Delirium in Elderly Patients Undergoing Orthopaedic Surgery.

Study Overview
=================
Brief Summary
-----------------
Postoperative delirium is a common and important complication in patients. The aim of this study was to investigate whether preoperative anxiety predicted onset of postoperative delirium in elderly patients undergoing orthopaedic surgery, so as to help develop preventive approaches.

Official Title
-----------------
Effect of Preoperative Anxiety on Postoperative Delirium in Elderly Patients Undergoing Orthopaedic Surgery.

Conditions
-----------------
Delirium, Anxiety

Intervention / Treatment
-----------------
* Behavioral: preoperative anxiety


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 65 or older patients undergoing elective orthopaedic surgery ASA I-III Exclusion Criteria: history of craniocerebral trauma surgery or severe central nervous system disease inability to read or understand the informed consent documents too physically or psychologically ill

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with preoperative anxiety<br> | Behavioral: preoperative anxiety<br>* patients who are anxious<br>|
| patients without preoperative anxiety<br> | Behavioral: preoperative anxiety<br>* patients who are anxious<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of postoperative delirium | postoperative delirium is diagnosed using CAM | 5-day postoperative period |
The Acute Effect of Moderate Intensity Stair-Climbing on Postprandial Blood Glucose

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the effect of moderate intensity stair-climbing bouts of various durations on postprandial blood glucose. Participants will perform a standard oral glucose tolerance test (OGTT) using 75g of dextrose and with fingerstick blood glucose measurements at baseline and every 15 minutes after consuming the drink for one hour. On separate subsequent visits, participants will perform the same OGTT combined with three stair-climbing bouts lasting 1, 3, and 10 minutes starting 27, 25, and 18 minutes respectively after finishing the drink. Participants performed maximal aerobic capacity (VO2max) using a ramp treadmill test in order to assess the relative intensity of each stairclimbing trial.

Official Title
-----------------
The Acute Effect of Moderate Intensity Stair-Climbing on Postprandial Blood Glucose

Conditions
-----------------
Postprandial Hyperglycemia

Intervention / Treatment
-----------------
* Other: Stair-climbing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Defined as low risk per the American College of Sports Medicine (ACSM, Guidelines for Exercise Testing & Exercise Prescription, 20014 pg 30) Physical Activity Recall Questionnaire (PAR-Q) screening Exclusion Criteria: Glucose intolerance Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Control<br>Oral glucose tolerance test with no stair-climbing | Other: Stair-climbing<br>* Short bouts of moderate intensity stair-climbing<br>|
| Experimental: 1 minute<br>Oral glucose tolerance test with 1 minute of stair-climbing | Other: Stair-climbing<br>* Short bouts of moderate intensity stair-climbing<br>|
| Experimental: 3 minutes<br>Oral glucose tolerance test with 3 minutes stair-climbing | Other: Stair-climbing<br>* Short bouts of moderate intensity stair-climbing<br>|
| Active Comparator: 10 minutes<br>Oral glucose tolerance test with 10 minutes stair-climbing | Other: Stair-climbing<br>* Short bouts of moderate intensity stair-climbing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial Blood Glucose | Postprandial blood glucose after various durations of stair-climbing | 1 hour |
Degenerative Scoliosis

Study Overview
=================
Brief Summary
-----------------
Several deformities of the spine exist such as degenerative lumbar scoliosis. These deformities can generate functional discomfort and limit the patient's quality of life. In the event of severe trunk imbalance and progression of the deformity, operative correction of the spinal deformity by instrumentation and posterior arthrodesis may be indicated. Surgical techniques and instrumentation have evolved over the past 5 years. These changes in surgical strategies have a potential impact on the patient's quality of life and the correction results in the medium and long term. The aim of the study is the analysis of surgical corrections obtained and radiological changes over time with classic 2-rod techniques versus modern 4-rod instrumentation techniques

Official Title
-----------------
Retrospective Analysis of Degenerative Scoliosis Corrections by Posterior Instrumentation

Conditions
-----------------
Degenerative Scoliosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subjects> 18 years old Subject with a surgical indication for arthrodesis and surgical correction of degenerative scoliosis Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. Exclusion criteria: Subject having expressed opposition to participating in the study Subject under guardianship or guardianship Subject under safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of degenerative scoliosis corrections by posterior instrumentation |  | Files analysed retrospectively from January 01, 2010 to December 31, 2010 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Degenerative Scoliosis, Degenerative lumbar scoliosis, Scoliosis